Drug Trial Radar · NCT07772960
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Oct 31, 2031
Study completion Oct 31, 2031
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 68 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.
Conditions
- Alcohol Use Disorder (AUD)
- Obesity (BMI Equal to or >30)
Interventions
PlaceboOther
Placebo - administered one weekly for 20 weeks
Semaglutide 1.0 mgDrug
Semaglutide 1.0 mg low dose
Semaglutide 2.0 mgDrug
Semaglutide 2.0 mg high dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alcohol use daysTime frame: 20 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Yale Stress Center
New Haven, Connecticut · Recruiting
Yale Stress Center
New Haven, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.